- Previous Close
0.6300 - Open
0.6250 - Bid 0.6500 x --
- Ask 0.6900 x --
- Day's Range
0.6250 - 0.6700 - 52 Week Range
0.5150 - 0.9850 - Volume
114,204 - Avg. Volume
125,612 - Market Cap (intraday)
83.26M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.
argenica.com.auRecent News: AGN.AX
View MorePerformance Overview: AGN.AX
Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AGN.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AGN.AX
View MoreValuation Measures
Market Cap
83.26M
Enterprise Value
67.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.97
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-210.92%
Return on Assets (ttm)
-27.35%
Return on Equity (ttm)
-50.70%
Revenue (ttm)
2.6M
Net Income Avi to Common (ttm)
-5.48M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
15.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.11M